Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650078 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis
A Phase 3 study of Rheumatoid Arthritis, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT00650078 is a Phase 3 study of Rheumatoid Arthritis that has completed, run by Amgen. The registered enrollment target is 350 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00650078, a Phase 3 study of Rheumatoid Arthritis, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to compare the safety and efficacy, with regards to the signs and symptoms, of MR prednisone (Lodotra®) versus placebo in combination with standard Disease Modifying Anti-Rheumatic Drug (DMARD) treatment in patients with active rheumatoid arthritis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MR prednisone
Study Locations (20)
California
- The National Institute of Clinical Research - Los Angeles
- University of California, Los Angeles - Los Angeles
- Blue Hill Medical Group - Pacific Palisades
- San Diego Arthritis Medical Clinic - San Diego
- Boling Clinical Trials - Upland
Florida
- Arthritis Center - Palm Harbor
- West Broward Rheumatology Associates, Inc. - Tamarac
- Southwest Florida Clinical Research Center - Tampa
- Tampa Medical Group, PA - Tampa
- Geodyssey Research, LLC - Vero Beach
Colorado
- Lynn Institute of the Rockies - Colorado Springs
- Front Range Clinical Research - Wheat Ridge
Alabama
- Rheumatology Associates of N. AL, P.C. - Huntsville
Arizona
- ArthoCare, Arthritis Care & Research, P.C. - Phoenix
Illinois
- The Arthritis Center - Springfield
Kentucky
- Center for Arthritis and Osteoporosis - Elizabethtown
Massachusetts
- Phase III Clinical Research - Fall River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650078
The ClinicalTrials.gov registry entry for NCT00650078 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (93% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00650078 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00650078 about?
NCT00650078 is a clinical study titled "Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis". The purpose of the study is to compare the safety and efficacy, with regards to the signs and symptoms, of MR prednisone (Lodotra®) versus placebo in combination with standard Disease Modifying Anti-Rheumatic Drug (DMARD) treatment in patients with active rheumatoid arthritis.
What is the current status of trial NCT00650078?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2008-03. Estimated completion is 2009-05.
What conditions does trial NCT00650078 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00650078?
The interventions under investigation include: Placebo (DRUG), MR prednisone (DRUG).
Who is sponsoring clinical trial NCT00650078?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00650078 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Ra-pro Pragmatic Trial
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.